Another one of Paolo Macchiarini’s past trachea transplant patients has died on 9 July 2018. She received from Macchiarini a cadaveric decellurised trachea in December 2010. By 2018, Zhadyra’s situation critically deteriorated, the dying patient was used for another experiment. On June 5th 2018, Zhadyra received in Moscow another trachea transplant. Responsible was same Parshin who performed the first trachea transplant together with Macchiarini.
Paloma was supposed to the second trachea transplant patient of Paolo Macchiarini’s in Barcelona, in summer 2008. The scandal surgeon gave her a fake diagnosis of a lethal tracheal cancer which she never had, and also “accidentally” mislocated her stent during a enforced bronchoscopy. All to coerce his patient to agree to a trachea transpalnt. Paloma had a lucky escape, twice. She namely also encountered Thorsten Walles.
In the aftermath of the scandal around Paolo Macchiarini, which left many patients dead, his former employer Karolinska Institutet requested a retraction a paper. The Swiss-German medical publisher Karger and its journal Respiration however categorically refused and ordered KI not “to patronize the readers of the journal ‘Respiration’.” The German Editor-in-Chief had namely a huge conflict of interest.
In 2017, UCL invited an external expert commission to investigate the deadly trachea transplants performed by the former UCL honorary professor Paolo Macchiarini. An already sacked UCL nanotechnology professor, Alexander Seifalian, whose lab made the two UCL plastic POSS-PCU tracheas in 2011, was announced as the main culprit on UCL side. All this despite Seifalian’s having had no clinical role, training or ambitions, as he professed in his interview to the investigative committee, which I now obtained.
What with the EU phase 2 clinical trial TETRA going nowhere, the technology’s owner, Liverpool-based company Videregen decided to seek new clinical partners. Surgeons and universities from outside the EU are invited to test Videregen’s trachea transplant technology, which was originally developed together with Paolo Macchiarini by the UCL laryngologist and paid Videregen advisor Martin Birchall.
German diabetologist Kathrin Maedler is a central figure of a questionable academic dynasty. Using Photoshop simulations, she discovered a cure for diabetes, which was then allegedly validated in clinical trials led by her Swiss PhD advisor Marc Donath. 15 years later, the Maedler-Donath diabetes cure was proven as utterly ineffective by same Donath, in another clinical trial. Maedler’s own PhD student, Amin Ardestani is group leader in Bremen, despite data irregularities and unacknowledged textual reuse in his thesis.
Imagine you are Martin Birchall, laryngologist and ENT surgeon, star of regenerative medicine at UCL and trachea transplant enthusiast. You and your business partner Videregen need to explain to EU bureaucrats why your technology of decellurised cadaveric trachea is perfectly safe, what with all the dead patients of yours and your former best friend Paolo Macchiarini. Yet both your trachea transplant pigs die. EU authorities however accept this as proof that your method is safe!